Susan H. Fox

TL;DR: In this article, the authors used deep learning pose estimation algorithms for vision-based assessment of parkinsonism and levodopa-induced dyskinesia (LID) and demonstrated promising performance for the future translation of deep learning to clinical practices.

TL;DR: The first report of a 'clinically important change' for dyskinesia rating scales in phase II clinical trials is provided, providing early knowledge of a CIC that may help inform the decision to advance into phase III trials and contribute for a higher yield of success in finding new anti-dyskinetic treatments.

TL;DR: Patients with neurodegenerative diseases showed alterations in connectivity in brain regions important for social cognition compared with HCs, and functional connectivity correlated with performance on social cognition tasks and alterations could be responsible for some of the social cognition deficits observed in all neurodegenersative diseases.

TL;DR: The opportunity for repurposing drugs for use in l-DOPA-induced dyskinesia (LID) in Parkinson's disease is discussed and development strategies that might progress such a candidate towards a Phase II clinical PoC are discussed.

TL;DR: To report on the clinical efficacy of bilateral globus pallidus internus deep brain stimulation in a 29‐year‐old patient with severe generalized dystonia secondary to Wilson's disease.